TIDMEKF

RNS Number : 9564P

EKF Diagnostics Holdings PLC

25 October 2021

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Dividend confirmation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business , announces that the Board has confirmed a cash dividend of 1.1p per ordinary share which will be paid on 1 December 2021.

The dividend timetable dates are below:

 
 Ex-dividend     4 November 2021 
  date: 
 Record date:    5 November 2021 
 Payment date:   1 December 2021 
 
 
EKF Diagnostics Holdings plc                                    www.ekfdiagnostics.com 
Christopher Mills, Non-executive Chairman                     Tel: +44 (0)29 2071 0570 
Mike Salter, CEO 
Richard Evans, FD & COO 
 
Singer Capital Markets (Nominated Adviser &                  Tel: +44 ( 0)20 7496 3000 
 Joint Broker) 
Aubrey Powell / George Tzimas / Tom 
 Salvesen 
 
Investec Bank plc (Joint Broker)                              Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited                     Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth            Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                   303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DIVUUSWRAWURURA

(END) Dow Jones Newswires

October 25, 2021 02:00 ET (06:00 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Ekf Diagnostics.
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Ekf Diagnostics.